Abstract
As a continuing and exploratory work on diarylpyrimidines (DAPYs) as human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) inhibitors, bulky and electron-rich naphthyl was introduced into the structure of DAPYs to replace the phenyl left wing of DAPYs, which is aimed to improve the π–π stacking interactions between inhibitors and some aromatic amino acid residues within the binding pocket of RT. The title compound 1a, with a 1-naphthyl left wing, displayed good inhibitory activity against wild-type HIV-1 (EC50 = 0.071 μM), along with moderate inhibitory activity against HIV-2 (EC50 = 6.5 μM).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chan JH, Freeman GA, Tidwell JH, Romines KR, Schaller LT, Cowan JR, Gonzales SS, Lowell CW, Andrews C III, Reynolds DJ, St. Clair M, Hazen RJ, Ferris RG, Creech KL, Roberts GB, Short SA, Weaver K, Koszalka GW, Boone LR (2004) Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem 47:1175–1182
Chen X, Zhan P, Li D, De Clercq E, Liu X (2011) Recent advances in DAPYs and related analogues as HIV-1 NNRTIs. Curr Med Chem 18:359–376
De Clercq E (2001) New developments in anti-HIV chemotherapy. Curr Med Chem 8:1543–1572
Feng X-Q, Liang Y-H, Zeng Z-S, Chen F-E, Balzarini J, Pannecouque C, De Clercq E (2009) Structural modifications of DAPY analogues with potent anti-HIV-1 activity. ChemMedChem 4:219–224
Gu SX, He QQ, Yang SQ, Ma XD, Chen FE, De Clercq E, Balzarini J, Pannecouque C (2011a) Synthesis and structure–activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs. Bioorg Med Chem 19:5117–5124
Gu SX, Zhang X, He QQ, Yang LM, Ma XD, Zheng YT, Yang SQ, Chen FE (2011b) Synthesis and biological evaluation of naphthyl phenyl ethers (NPEs) as novel nonnucleoside HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem 19:4220–4226
Ji L, Chen FE, Feng XQ, De Clercq E, Balzarini J, Pannecouque C (2006) Non-nucleoside HIV-1 reverse transcriptase inhibitors, part 7. Synthesis, antiviral activity, and 3D-QSAR investigations of novel 6-(1-naphthoyl) HEPT analogues. Chem Pharm Bull 54:1248–1253
Ji L, Chen F-E, De Clercq E, Balzarini J, Pannecouque C (2007) Synthesis and anti-HIV-1 activity evaluation of 5-alkyl-2-alkylthio-6-(arylcarbonyl or α-cyanoarylmethyl)-3,4-dihydropyrimidin-4(3H)-ones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. J Med Chem 50:1778–1786
Liang Y-H, Chen F-E (2009) QSAR studies for diarylpyrimidines against HIV-1 reverse transcriptase wild-type and mutant strains. Eur J Med Chem 44:625–631
Ludovici DW, De Corte BL, Kukla MJ, Ye H, Ho CY, Lichtenstein MA, Kavash RW, Andries K, de Béthune MP, Azijn H, Pauwels R, Lewi P, Heeres J, Koymans LMH, de Jonge MR, Van Aken KJA, Daeyaert FFD, Das K, Arnold E, Janssen PAJ (2001a) Evolution of anti-HIV drug candidates. Part 3: diarylpyrimidine (DAPY) analogues. Bioorg Med Chem Lett 11:2235–2239
Ludovici DW, Kavash RW, Kukla MJ, Ho CY, Ye H, Corte BLD, Andries K, de Béthune M-P, Azijn H, Pauwels R, Moereels HEL, Heeres J, Koymans LMH, de Jonge MR, Van Aken KJA, Daeyaert FFD, Lewi PJ, Das K, Arnold E, Janssen PAJ (2001b) Evolution of anti-HIV drug candidates. part 2:diaryltriazine (DATA) analogues. Bioorg Med Chem Lett 11:2229–2234
Mehellou Y, De Clercq E (2010) Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? J Med Chem 53:521–538
Meng G, Chen FE, De Clercq E, Balzarini J, Pannecouque C (2003) Nonnucleoside HIV-1 reverse transcriptase inhibitors: part I. Synthesis and structure–activity relationship of 1-alkoxymethyl-5-alkyl-6-naphthylmethyl uracils as HEPT analogues. Chem Pharm Bull 51:779–789
Pannecouque C, Daelemans D, De Clercq E (2008) Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later. Nat Protoc 3:427–434
Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, Desmyter J, De Clercq E (1988) Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 20:309–321
Radi M, Falciani C, Contemori L, Petricci E, Maga G, Samuele A, Zanoli S, Terrazas M, Castria M, Togninelli A, Esté JA, Clotet-Codina I, Armand-Ugón M, Botta M (2008) A multidisciplinary approach for the identification of novel HIV-1 non-nucleoside reverse transcriptase inhibitors: S-DABOCs and DAVPs. ChemMedChem 3:573–593
Romines KR, Freeman GA, Schaller LT, Cowan JR, Gonzales SS, Tidwell JH, Andrews CW III, Stammers DK, Hazen RJ, Ferris RG, Short SA, Chan JH, Boone LR (2006) Structure–activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor. J Med Chem 49:727–739
Rotili D, Tarantino D, Artico M, Nawrozkij MB, Gonzalez-Ortega E, Clotet B, Samuele A, Esté JA, Maga G, Mai A (2011) Diarylpyrimidine–dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level. J Med Chem 54:3091–3096
Sweeney ZK, Kennedy-Smith JJ, Wu J, Arora N, Billedeau JR, Davidson JP, Fretland J, Hang JQ, Heilek GM, Harris SF, Hirschfeld D, Inbar P, Javanbakht H, Jernelius JA, Jin Q, Li Y, Liang W, Roetz R, Sarma K, Smith M, Stefanidis D, Su G, Suh JM, Villaseñor AG, Welch M, Zhang F-J, Klumpp K (2009) Diphenyl ether non-nucleoside reverse transcriptase inhibitors with excellent potency against resistant mutant viruses and promising pharmacokinetic properties. ChemMedChem 4:88–99
Wang YP, Chen FE, Balzarini J, De Clercq E, Pannecouque C (2008) Non-nucleoside HIV-1 reverse-transcriptase inhibitors part 101) synthesis and anti-HIV activity of 5-alkyl-6-(1-naphthylmethyl)pyrimidin-4(3h)-ones with a mono- or disubstituted 2-amino function as novel dihydro-alkoxy-benzyl-oxopyrimidine/(DABO) analogues. Chem Biodivers 5:168–176
Xiong YZ, Chen FE, Balzarini J, De Clercq E, Pannecouque C (2008) Non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 11: structural modulations of diaryltriazines with potent anti-HIV activity. Eur J Med Chem 43:1230–1236
Zeng ZS, Liang YH, Feng XQ, Chen FE, Pannecouque C, Balzarini J, De Clercq E (2010) Lead optimization of diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. ChemMedChem 5:837–840
Acknowledgments
We are grateful to the National Natural Science Foundation of China (No. 30672536), the K.U. Leuven (GOA No. 10/14), and Hubei Provincial Department of Education (No. Q20141505, No. XD2014154), Wuhan Institute of Technology Scientific Research Fund (No. 10128301) for the financial support of this research. We thank Mrs. K. Erven, Mr. K. Uyttersprot, and Mr. Hua-Wei Liu for excellent technical assistance.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Gu, SX., Zhu, YY., Chen, FE. et al. Structural modification of diarylpyrimidine derivatives as HIV-1 reverse transcriptase inhibitors. Med Chem Res 24, 220–225 (2015). https://doi.org/10.1007/s00044-014-1119-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00044-014-1119-5